A Boston jury last week ordered Pfizer Inc. to pay $47 million in damages in a lawsuit over its epilepsy drug Neurontin. The lawsuit claimed that the drug giant had marketed Neurontin for unapproved uses, which violates federal racketeering laws. While doctors are free to prescribe medicines as they see fit, drugmakers are only allowed to [...]
Posts Tagged ‘off label marketing’
PFIZER ORDERED TO PAY $41 MILLION FOR OFF LABEL MARKETING
Posted: March 25, 2010 by administrator in FCRATags: Alabama False Claims Act Lawyer, Neurontin Unapproved Uses, off label marketing, off label promotion, Pfizer, qui tam lawyer
0
Johnson & Johnson Off Label Marketing Kickback Lawsuit Filed
Posted: March 10, 2010 by administrator in FCRATags: Anti-psychotic drugs, false claims act, john & johnson, kickback lawsuit, marketing scheme, off label marketing, Omnicare lawsuit, qui tam lawsuit
The Massachusetts Attorney General has joined in a lawsuit against Johnson & Johnson that claims the company paid out millions of dollars to get its anti-psychotic drugs prescribed in nursing homes. Anti-psychotic drugs may be prescribed “off-label” to treat dementia, as is done in many nursing homes, but companies are prohibited from marketing or promoting [...]
$3.76 Million Qui Tam Settlement
Posted: March 7, 2010 by administrator in FCRATags: false claims act, government fraud, medicare fraud, off label marketing, qui tam, relator, whistle blower
The Ohio based medical device manufacturer, Atricure, Inc., has settled a qui tam lawsuit that alleged Atricure marketed its medical devices for off label uses. In other words, Atricure promoted its medical devices for purposes other than for which the FDA approved its devices. According to the Department of Justice, the allegations were made against Atricure in [...]
Novartis to Plead Guilty to Criminal Fraud Charges
Posted: March 5, 2010 by administrator in CONSUMER FRAUDTags: CONSUMER FRAUD, false claims act, novartis, off label marketing, off label promotion, pharm fraud, qui tam
The swiss drug manufacturer said it will plead guilty to criminal fraud charges arising out of its alleged off-label marketing of its epilepsy drug, Trileptal. In addition, Novartis will pay a $185 million dollar fine. Novartis is also being investigated for kick backs and off-label marketing of other drugs, such as Diovan, Exforge, Sandostatin, Tekturna and Zelnorm. [...]